Clearmind Medicine Inc. (NASDAQ:CMND) Short Interest Update

Clearmind Medicine Inc. (NASDAQ:CMND) was the recipient of a significant decrease in short interest in August. As of August 31st, there was short interest totaling 25,174 shares, a decrease of 48.9% from the August 15th total of 49,268 shares. Approximately 2.5% of the company’s stock are sold short. Based on an average daily volume of 188,915 shares, the days-to-cover ratio is presently 0.1 days.

Clearmind Medicine Price Performance

Shares of NASDAQ CMND opened at $0.81 on Thursday. The company has a current ratio of 4.31, a quick ratio of 4.31 and a debt-to-equity ratio of 0.01. Clearmind Medicine has a twelve month low of $0.79 and a twelve month high of $524.00. The stock has a 50 day moving average of $1.63 and a two-hundred day moving average of $4.63. The stock has a market cap of $822,018.00, a P/E ratio of -0.02 and a beta of 0.81.

Clearmind Medicine (NASDAQ:CMND) last announced its earnings results on Thursday, September 10th. The company reported ($0.57) earnings per share (EPS) for the quarter.

Wall Street Analysts Forecast Growth

Separately, Wall Street Zen raised shares of Clearmind Medicine from a “strong sell” rating to a “sell” rating in a report on Saturday, June 20th.

Clearmind Medicine Company Profile

Clearmind Medicine, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel psychoplastogen-based therapeutics for neuropsychiatric and neurodegenerative disorders. The company leverages a proprietary chemistry platform to design small-molecule compounds that promote rapid and sustained neural plasticity without the hallucinogenic effects typically associated with psychedelic agents. By targeting fundamental mechanisms of synaptic growth and repair, Clearmind aims to address conditions ranging from mood and anxiety disorders to cognitive impairment in dementia.

Clearmind’s pipeline includes multiple preclinical and early clinical candidates.